Join the Rifampin group to help and get support from people like you.
Rifampin News
Three All-Oral Shortened Regimens Noninferior for Rifampin-Resistant TB
THURSDAY, Feb. 6, 2025 – Three all-oral shortened regimens have noninferior efficacy compared with standard therapy for fluoroquinolone-susceptible, rifampin-resistant tuberculosis, according to a...
Kansas Reports Largest Tuberculosis Outbreak in U.S. History
TUESDAY, Jan. 28, 2025 – Kansas health officials are fighting the largest tuberculosis (TB) outbreak in U.S. history, with 67 confirmed cases since new year began. The outbreak includes 60 active...
Shorter Treatment Regimens Recommended for Tuberculosis
MONDAY, Jan. 13, 2025 – In a clinical practice guideline issued by the American Thoracic Society and published in the January issue of the American Journal of Respiratory and Critical Care Medicine,...
Once Again, Tuberculosis Becomes World's Top Infectious Disease Killer
WEDNESDAY, Oct. 30, 2024 – In the highest tally ever recorded for tuberculosis cases, the World Health Organization reported Tuesday that over 8 million people worldwide were diagnosed with the lung...
FDA Medwatch Alert: Colistimethate for Injection USP, 150 mg and Rifampin for Injection USP, 600 mg/vial by Heritage Pharmaceuticals: Recall - Lack of Sterility Assurance
ISSUE: Heritage Pharmaceuticals Inc. announced the voluntary nationwide recall of ten (10) lots of Colistimethate for Injection, USP, 150 mg Single-Dose vial (NDC 23155-193-31) and three (3) lots of ...